Clinical trials: SCI - Spinal Cord Injury
Amyotrophic Lateral Sclerosis, Neuromuscular Disease
Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)
The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI).
- Conditions
- Amyotrophic Lateral Sclerosis, Neuromuscular Disease, Stroke, Tetraplegia/Tetraparesis
- Trial name
- CONNECT-ONE (NCT07357428)
- Testing
- Connexus Brain-Computer Interface
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Paradromics
Paraplegia, Spinal Cord Injuries (SCI)
Safety and Performance Evaluation of ReWalk Reciprocating Gait Orthosis (RGO)
ReWalk suit developed by Argo Medical Technologies is designed to enable people with lower limb disabilities to carry out routine ambulatory functions (stand, walk etc.); it can be used by people with disabilities such as spinal…
- Trial name
- NCT01251549
- Testing
- ReWalk - a motorized exoskeleton suit
- Where
- 2 sites in United States, Italy
- Volunteers
- 32 people
- Sponsor
- ReWalk Robotics, Inc.
Lower Extremity Motor Dysfunction, Spinal Cord Injury
Evaluation of the Effectiveness and Safety of AI-Robotics
Evaluation of the effectiveness and safety of the lower extremity exoskeleton rehabilitation training robot
- Trial name
- ART (NCT03452059)
- Testing
- AiLegs, AiWalker and HKAFO
- Where
- China
- Volunteers
- 40 people
- Sponsor
- AI-Robotics Technology Co., Ltd
Spinal Cord Injury, Orthostatic Hypotension
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord Injury
The goal of this interventional study is to evaluate the safety and preliminary effectiveness of the ARC-IM Therapy to improve hemodynamic management in people with sub-acute or chronic spinal cord injury.
- Trial name
- HemON-NL (NCT05941819)
- Testing
- ARC-IM Thoracic System implantation
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- ONWARD Medical, Inc.
Traumatic Thoracic Acute Spinal Cord Injury
The INSPIRE Study: Probable Benefit of the Neuro-Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury
This is an HDE probable benefit, open-label, non- randomized, single-arm, multicenter study to evaluate the safety and probable benefit of the poly(lactic-co-glycolic acid)-b-poly(L-lysine) Scaffold ("Scaffold") in subjects with…
- Trial name
- NCT02138110
- Testing
- Neuro-Spinal Scaffold
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- InVivo Therapeutics
Spinal Cord Injury at C5-C7 Level
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI
This study is expanded access to an Investigational New Drug (IND) for an individual patient with spinal cord injury (SCI) at cervical spine 5-6 (C 5-6) designed to provide access to autologous adipose-derived mesenchymal stem…
- Trial name
- NCT03925649
- Testing
- HB-adMSCs
- Where
- United States
- Sponsor
- Hope Biosciences LLC
Urinary Retention, Neurogenic Bladder
Connected Catheter (C2P) Study for Bladder Management
The objective of this study is to evaluate the safety and essential performance of the C2P System in males with neurogenic lower urinary tract dysfunction (NLUTD), both in an acute clinical setting and an extended period of home…
- Trial name
- NCT03626324
- Testing
- C2P
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spinal Singularity
Muscle Spasticity
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury
- Trial name
- NCT00557973
- Testing
- XP19986 SR1, 10 mg BID, XP19986 SR1, 20 mg BID, XP19986 SR1, 30 mg BID
- Where
- 11 sites in United States
- Volunteers
- 37 people
- Sponsor
- XenoPort, Inc.
Spinal Cord Injuries, Paraplegia and Tetraplegia
Self-balancing Personal Exoskeleton for SCI (WIP)
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
- Trial name
- NCT07536386
- Testing
- Hands-free exoskeleton
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Wandercraft
Spinal Cord Injury
Performance Attributes and User Progression While Using Ekso
This study is to evaluate the performance attributes and user progression of participants with motor complete and incomplete spinal cord injury (SCI) while utilizing the Ekso robotic exoskeleton in an eight week over ground…
- Trial name
- NCT02132702
- Testing
- Ekso
- Where
- 9 sites in Denmark, Germany and 5 more
- Volunteers
- 60 people
- Sponsor
- Ekso Bionics
Cervical Spinal Cord Injury
Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury
This is an one arm study to be conducted in spinal cord injury patients. The goal of this clinical trial is to learn if rimonabant improves hand motor and performance function in patients with cervical spinal cord injury.
- Trial name
- RIMOHANDOPEN (NCT07843108)
- Testing
- Rimonabant
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Sinfatin S.L
Tetraplegia/Tetraparesis, Quadriplegia
Precise Robotically IMplanted Brain-Computer InterfacE
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or…
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
- Trial name
- PRIME (NCT06429735)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Neuralink Corp
Spinal Cord Injuries
LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1
This is a LTFU study for cervical SCI subjects that were administered AST-OPC1 cells in the main study AST-OPC1-01.
- Trial name
- NCT05975424
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Lineage Cell Therapeutics, Inc.
Spinal Cord Injury (SCI)
Safety and Usability of the ATLAS 2030 Exoskeleton in Pediatric Patients With Spinal Cord Injury
The goal of this clinical trial is to analyze the usability and safety of the robotic gait ATLAS 2030 in a cohort of pediatric patients with Spinal Cord Injury, with the aim of extending its indication for use to pediatric spinal…
- Trial name
- NCT06772077
- Testing
- Rehabilitation treatment with ATLAS2030
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- MarsiBionics
Spinal Cord Injury, Muscle Spasticity
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs.
- Trial name
- NCT00041717
- Testing
- Fampridine-SR
- Where
- 45 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Acorda Therapeutics
Spinal Cord Injuries, Acute Spinal Cord Injury
Stem Cells in Spinal Cord Injury
This is a multicenter, randomized, double-blind, placebo-controlled and delayed-start phase II/III clinical study.
- Conditions
- Spinal Cord Injuries, Acute Spinal Cord Injury, Paraplegia, Spinal, Paraplegia; Traumatic
- Trial name
- SCI2 (NCT03935724)
- Testing
- Neuro-Cells
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 16 people
- Sponsor
- Neuroplast
Acute Spinal Cord Injury
AC105 in Patients With Acute Traumatic Spinal Cord Injury
The principal aim of this study was to establish the feasibility of rapid administration, safety, and tolerability of AC105 in patients with acute spinal cord injury.
- Trial name
- AC105 (NCT01750684)
- Testing
- AC105
- Volunteers
- 15 people
- Sponsor
- Acorda Therapeutics
Spinal Cord Injuries
Phase I/II Study of KP-100IT in Acute Spinal Cord Injury
This study is randomized, double-blind, placebo-controlled Phase I/II study designed to evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation for intrathecal injection, as a treatment for…
- Trial name
- NCT02193334
- Testing
- KP-100IT
- Where
- 2 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Kringle Pharma, Inc.
Cervical Spinal Cord Injury
Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
The purpose of this study is to determine the efficacy and safety of VX-210 in subjects with Acute Traumatic Cervical Spinal Cord Injury.
- Trial name
- NCT02669849
- Testing
- VX-210
- Where
- 39 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Spinal Cord Injury
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
This study will evaluate the acute safety, tolerability, feasibility and pharmacokinetics of 6 dose regimens of ATI355 in acute spinal cord injury patients
- Trial name
- NCT00406016
- Testing
- ATI355
- Where
- 14 sites in Canada, Germany and 1 more
- Volunteers
- 52 people
- Sponsor
- Novartis